Multicenter, randomized, placebo-controlled, double-blind clinical trial of escitalopram on the progression-delaying effects in Alzheimer's disease

详细信息    查看全文

• 作者：Young Min Choe ; Ki Woong Kim ; Jin Hyeong Jhoo ; Seung Ho Ryu ; Eun Hyun Seo ; Bo Kyung Sohn ; Min Soo Byun ; Jae-Hwa Bak ; Jong-Min Lee ; Hyuk Jin Yun ; Myeong-il Han ; Jong Inn Woo and Dong Young Lee
• 刊名：International Journal of Geriatric Psychiatry
• 出版年：2016
• 出版时间：July 2016
• 年：2016
• 卷：31
• 期：7
• 页码：731-739
• 全文大小：412K
• ISSN：1099-1166

文摘

A series of preclinical studies have suggested that selective serotonin reuptake inhibitor antidepressants not only stimulate neurogenesis but also have neuroprotective effects. The present study primarily aimed to investigate whether escitalopram would decelerate the brain atrophy of patients with mild-to-moderate Alzheimer's disease (AD). We also assessed the effects of escitalopram on the cognitive function and neuropsychiatric symptoms of these participants.